Medicago inc.: federal grants and contributions: 5 agreements; $188M value; 3 departments; 5 programs.
Assay record ASY-CA-0EQVAAJ099 · Cite as: Assay Systems, “Medicago inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/medicago-inc/
The Project is in direct response to the global fight against COVID-19. The Project will be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.
Monies allocated over more than one fiscal year;Repayable Contribution
Acquisition of equipment: The project is part of an overall plan to build a complex that includes the head office, R&D laboratories, a pilot plant and a commercial plant for a company specializing in the development and commercialization of vaccines and therapeutic proteins.
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Monies allocated over more than one fiscal year;Repayable Contribution
All grants from Innovation, Science and Economic Development Canada
All grants from Canada Economic Development for Quebec Regions
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.